The legal library gives you easy access to the FTC’s case information and other official legal, policy, and guidance documents.
FTC Staff Comment to the Honorable Dennis Stapleton Concerning Ohio H.B. 325 to Permit Competing Health Care Providers to Engage in Collective Bargaining With Health Plans
Farpoint Services Int'l, Ltd., Garrison Corporation, Inc., American Card Services, et al.
20021184: Ripplewood Partners, L.P.; Robert H. Baker
0209010 Informal Interpretation
Prepared Statement of the Federal Trade Commission On State Impediments To E-commerce
20021178: Landry's Restaurants, Inc.; Metro National Corporation
20021157: Pentair, Inc.; Vivendi Environnement, S.A.
20021151: Groupe Laperriere & Verreault Inc.; Baker Hughes Incorporated
Statement of Commissioner Mozelle W. Thompson - FTC v. Citigroup Inc., et al.
Prepared Statement of the Federal Trade Commission On Overview of Enforcement of the Antitrust Laws
International Trader, et al.
20021146: Robert Bosch Industrietreuhand KG; Koninklijke Philips Electronics N.V.
Rules Concerning Disclosures Regarding Energy Consumption and Water Use of Certain Home Appliances and Other Products Required Under the Energy Policy and Conservation Act ("Appliance Labeling Rule") - 16 CFR Part 305
Granting of Request for Early Termination of the Waiting Period Under the Premerger Notification Rules
20020851: Archer-Daniels-Midland Company; Minnesota Corn Processors, LLC
Amgen Inc. and Immunex Corporation
Amgen settled antitrust charges that its proposed $16 billion acquisition of Immunex Corporation would reduce competition and tend to create a monopoly in the biopharmaceutical markets for neutrophil (white blood cell) regeneration factors; tumor necrosis factor (TNF) inhibitors; and interleukin-1 (IL-1) inhibitors. The consent order requires the firms to sell all of Immunex's assets related to Leukine -a neutrophil regeneration factor -to Schering AG; license certain intellectual property rights to TNF inhibitors to Serono S.A.; and license certain intellectual property rights related to IL-1 inhibitors to Regeneron Pharmaceuticals Inc.